CXXC11 Inhibitors
Chemical inhibitors of CXXC11 can affect the protein's function through the modulation of various signaling pathways that are integral to its regulation. PD98059 and U0126, both inhibitors of MEK, can lead to the suppression of the ERK pathway, a signaling route that may be vital for the proper functioning of CXXC11. By impeding the activation of MEK, these inhibitors can diminish the phosphorylation and activation of downstream targets, potentially including CXXC11. Similarly, LY294002 and Wortmannin, which inhibit PI3K, can disrupt the PI3K/Akt pathway. This interruption can decrease the activity of proteins regulated by this pathway, which is likely to include CXXC11. The alteration in Akt activity can thus influence the cellular processes in which CXXC11 is involved.
Moreover, chemical inhibitors like SB203580, which targets p38 MAPK, and SP600125, which inhibits JNK, can affect CXXC11 by impeding the pathways responsible for stress response and other cellular signaling mechanisms. By inhibiting these kinases, the functional activity of CXXC11 can be reduced as a result of the suppressed stress response signaling. PP2, which inhibits Src family tyrosine kinases, and Gefitinib, which inhibits EGFR tyrosine kinase, can also lead to a decrease in CXXC11 activity by targeting key regulatory proteins involved in multiple signaling pathways that may control the function of CXXC11. Staurosporine, a broad-spectrum protein kinase inhibitor, can further inhibit various kinases that phosphorylate proteins, including CXXC11, thereby reducing CXXC11's activity. Bortezomib's proteasome inhibition can affect CXXC11 by causing an accumulation of misfolded proteins and inducing cellular stress responses. Finally, Thapsigargin disrupts calcium homeostasis by inhibiting the SERCA pump, which can lead to the functional inhibition of CXXC11 due to the pivotal role of calcium signaling in the regulation of various proteins.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of the MAP kinase kinase (MEK), which is upstream of the ERK pathway. Since CXXC11 is involved in DNA demethylation processes that can be responsive to signal transduction pathways, including the ERK pathway, inhibition of MEK by PD98059 can lead to reduced activity of downstream targets, including CXXC11. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream of the Akt signaling pathway. CXXC11, being responsive to cellular signaling, may be affected by the inhibition of PI3K as this would decrease Akt activity, subsequently influencing CXXC11's function in the cell. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 acts as an inhibitor of p38 MAPK, a protein kinase that is involved in signal transduction and could influence the activity of proteins like CXXC11, which are implicated in cellular response mechanisms. By inhibiting p38 MAPK, SB203580 can lead to the functional inhibition of CXXC11. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor, which, by inhibiting MEK1/2, prevents the activation of the ERK pathway. This can suppress the cellular processes that CXXC11 is part of, thereby inhibiting its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which affects transcription factors and other proteins involved in stress responses. Through inhibition of JNK, SP600125 can disrupt pathways that regulate the function of proteins like CXXC11. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K, and by inhibiting this kinase, it can disrupt the PI3K/Akt pathway, leading to a decrease in the functional activities of proteins such as CXXC11 that are potentially regulated by this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a central protein in a pathway that controls protein synthesis and cell growth. As mTOR can influence a wide array of proteins, including CXXC11, its inhibition by Rapamycin can functionally inhibit the activity of CXXC11. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. These kinases are involved in multiple signaling pathways that can regulate proteins like CXXC11. Inhibition of Src kinases by PP2 can reduce CXXC11 activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the regulation of various cellular pathways. By inhibiting EGFR, Gefitinib can indirectly lead to the inhibition of CXXC11. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor. Given that CXXC11's function could be regulated by phosphorylation through various kinases, staurosporine can inhibit those kinases, thereby inhibiting the function of CXXC11. | ||||||